Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
A new review confirms SGLT2 inhibitors help older adults with heart failure, and a stent choice affects transplant recovery
Today’s findings focus on two strong, practice-relevant topics: SGLT2 inhibitors for heart and kidney protection in older adults, and stent choice after transplant surgery. A smaller trial looked at curcumin versus pentoxifylline, but its size and design limit how much weight to give it. Most other studies were observational or background work, showing links without proving cause-and-effect.
Safety & efficacy of sodium glucose co-transport 2 (SGLT2) inhibitors in elderly patients with heart failure
SGLT2 inhibitors are pills first made for diabetes that also protect the heart and kidneys. This review pooled trial data on older adults with heart failure and found they cut hospital stays and deaths from heart causes, with safety much like younger patients. Side effects to watch were genital infections and dehydration. Most people with kidney disease also have heart disease, so this matters for both.
Double-J versus single-J stent placement in kidney transplant recipients: a systematic review and meta-analysis of postoperative outcomes
After a kidney transplant, surgeons place a small tube called a stent to keep the connection to the bladder open. This review pooled results from many studies comparing two stent designs, the double-J and the single-J, looking at problems after surgery. Pooling many studies gives a stronger answer than any one of them alone. This is a surgical detail that affects recovery, not long term kidney survival.
The effectiveness of nature-based interventions on mental health: A systematic review.
A large review of many studies found that spending time in nature — like walking in a park or gardening — lowered anxiety and depression symptoms, even in people with long-term health problems — but most studies were small and did not focus on kidney disease specifically.
A randomized controlled trial evaluating the impact of curcumin versus pentoxifylline on patients with chronic kidney disease
This was a randomized trial comparing curcumin, the yellow compound in turmeric, with pentoxifylline, a drug that improves blood flow, in people with chronic kidney disease. Both were tested as add-ons to usual care. The size of the trial and how long it ran are not stated in what we received, which matters a lot for how much weight to give it. Curcumin is a supplement, and supplements can interact with kidney medicines, so this is a question for her nephrologist, not a reason to start taking it.
Pharmacokinetics, Elimination and Dialyzability of HRS-9231 in Patients with Varying Degrees of Renal Impairment.
A new dye used in imaging tests was studied in 40 people with kidney disease, including those on dialysis — the study found how quickly the body removes it, which helps doctors choose safer doses.
Lifestyle Intervention and Its Effects on Inflammatory Cytokines and Oxidative Stress Markers in Diabetic Chronic Kidney Disease Patients: A Randomized Controlled Trial
A randomized trial tested a lifestyle program in people who have both diabetes and kidney disease. It measured inflammation markers and oxidative stress markers, which are blood signs of irritation and cell damage. The record we received does not say how many people took part or how long it ran, so the strength of the result cannot be judged. It also measured lab markers, not kidney function over time, so it does not show slower kidney decline.
Efficacy and safety of finerenone in adults with IgA nephropathy: a 12-month real-world study.
Among 142 adults with IgA nephropathy, the drug finerenone lowered protein in the urine by about 35% and slowed kidney filtering rate decline over 12 months — but this small real-world study lacked a comparison group, so the exact benefit is uncertain.
Broccoli Sprout Extract for Glycemic Management in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Trial.
In a small trial of 120 people with type 2 diabetes and stage 3b–4 kidney disease, those who took broccoli sprout extract for 12 weeks had blood sugar levels drop about 0.8% on average, compared to almost no change in the placebo group.
Association of semaglutide use with kidney outcomes in adults with ADPKD: A propensity score-matched real-world study.
Researchers looked back through a large database of health records for adults with polycystic kidney disease, an inherited condition that fills the kidneys with fluid sacs and slowly destroys them. They compared people who took semaglutide, a diabetes and weight loss drug, with closely matched people who did not, and left out anyone on the other kidney drugs. Because this used past records rather than a planned trial, it can show a link between the drug and kidney outcomes, not proof that the drug caused them. The summary available here does not give the result numbers.
Chronic Kidney Disease with Sjögren's Syndrome and Hyperthyroidism: Discrepant Creatinine- and Cystatin C-Based eGFR.
A 70-year-old woman had kidney disease, an overactive thyroid, and Sjogren's syndrome, an immune condition that dries out the eyes and mouth. Her two blood tests for kidney filtering rate (eGFR), one based on creatinine and one on cystatin C, gave very different answers. A kidney biopsy showed long-standing inflammation in the filtering tubes, and treating her thyroid brought the two numbers closer together. This is a report on one patient, so it flags a link worth knowing about, not proof of cause.
Urinary HSP90 as a Non-invasive Biomarker of Active Tubular Injury in Kidney Transplant Recipients: A Multicenter Prospective Study.
Researchers tested whether a protein called HSP90 in urine can show when the body is attacking a transplanted kidney. They collected 262 paired urine and blood samples from 112 transplant patients across several hospitals, looking for the common type of rejection that inflames the kidney's tubes. A urine test would be far easier than a biopsy, which takes a piece of the kidney with a needle. This kind of study shows a link between the protein and rejection, not proof that the test works in practice.
Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease.
Researchers looked at records of people who had just reached kidney failure and needed dialysis, comparing those taking GLP-1 drugs like semaglutide with those who were not. The people on these drugs went to hospital less often and were less likely to die. This is a look back at existing records, so it shows a link, not proof that the drug caused the benefit: people prescribed these drugs may be healthier to begin with. It matters because the big FLOW trial that proved semaglutide helps kidneys left out people already on dialysis.
Donor Self-Esteem Before and After Living Kidney Donation
This study followed people who gave a kidney while alive and asked how donating changed the way they felt about themselves. Most donors already feel good about themselves before surgery, and much less is known about the years afterward. The researchers also looked at whether shifts in self-esteem tracked with symptoms of depression and anxiety. This is observational work, so it can show links, not proof that donating causes the change.
Association Between Postoperative Platelet-to-Hemoglobin Ratio Trajectories and Acute Kidney Injury in Patients Undergoing Cardiac Surgery: A Retrospective Cohort Study with External Validation
This study looked back at patients who had heart surgery and tracked how their platelet count compared with their hemoglobin over the following days. Certain patterns in that ratio lined up with sudden kidney injury after surgery. The findings were checked against a second, separate group of patients, which makes the pattern more believable. It shows a link only, not cause, and this is a preprint that has not been through peer review.
Heart-type fatty acid-binding protein as a potential biomarker for hypertension in pediatric chronic kidney disease
Children with chronic kidney disease often develop high blood pressure, which speeds kidney damage. This study measured a blood protein called H-FABP, released when heart muscle is stressed, and found higher levels in the children with high blood pressure. It shows a link, not proof that the protein causes anything. It could become an early warning test, but it needs checking in larger groups first.
Longitudinal bone loss in patients with stage 3 CKD: a study based on densitometry and HR-pQCT
People with stage 3 kidney disease, meaning moderately reduced filtering, were followed over time with two kinds of bone scans. Their bone density dropped faster than expected, and the detailed scans showed thinning in the outer shell of bone, which raises fracture risk. This is an observational study, so it shows a link between kidney disease and bone loss, not proof of cause. It supports checking bone health earlier in kidney disease.
Acute kidney injury, baseline renal function, troponin, and survival after myocardial infarction
In people who had a heart attack, this study looked at whether sudden kidney injury, starting kidney function, and troponin, a blood marker of heart damage, predicted who survived. Weaker kidney function and a kidney injury during the hospital stay both tracked with worse survival. This is observational, so it shows a link, not proof that the kidney injury itself caused the deaths. The practical point: kidney numbers deserve attention during heart care, not just after it.
Factors associated with disease severity in adults with acute glomerulonephritis: a descriptive retrospective cohort study
This study looked back at adults hospitalized with acute glomerulonephritis, a sudden inflammation of the kidney's filters, to find what made some cases more severe. It identified factors that traveled with worse disease. Looking backward at records shows links, not causes, and the report is descriptive rather than a test of any treatment. It helps flag who is likely to get sicker, not what to do about it.
Fatal intoxication caused by conventional-dose methotrexate in an elderly patient with end-stage renal disease: A cautionary case report.
A 71-year-old man with rheumatoid arthritis and failing kidneys died after taking a normal low dose of methotrexate, a common arthritis drug. Healthy kidneys clear this drug from the body, so when they stop working the drug can build up to poisonous levels. This is a single case report, so it shows a link, not proof of cause. The authors flag it as a warning that standard doses can be dangerous in end-stage kidney disease.
Improving the Histologic Classification of Advanced Diabetic Nephropathy Based on the Transformative Research in Diabetic Nephropathy (TRIDENT) Findings
Diabetic kidney disease is the top cause of kidney failure worldwide, and doctors judge how bad it is by looking at a small piece of kidney tissue under a microscope. The scoring system used today does a poor job of predicting what happens next, especially in advanced disease. Researchers used the TRIDENT study to build a better scoring system. This is observational work, so it shows which tissue patterns go with worse outcomes, not what causes them.